The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Bradford Smith became the third patient to test Elon Musk's Neuralink — and the first one to do so without a voice.

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Brad Smith is the third person in the world to get a brain chip implant with Elon Musk's Neuralink, and the first nonverbal ...

A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...